gemcitabine
Selected indexed studies
- Barriers and opportunities for gemcitabine in pancreatic cancer therapy. (Am J Physiol Cell Physiol, 2023) [PMID:36571444]
- Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. (Gastroenterology, 2023) [PMID:36842710]
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. (J Clin Oncol, 2007) [PMID:17602081]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Barriers and opportunities for gemcitabine in pancreatic cancer therapy. (2023) pubmed
- Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. (2023) pubmed
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. (2007) pubmed
- Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. (2013) pubmed
- m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway. (2023) pubmed
- Gemcitabine-induced radiation recall. (2002) pubmed
- Gemcitabine in hematologic malignancies. (2001) pubmed
- Small Molecular Gemcitabine Prodrugs for Cancer Therapy. (2020) pubmed
- Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis. (2019) pubmed
- Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies. (2023) pubmed